Janux Therapeutics Shares Outstanding vs. Return On Asset
| JANX Stock | USD 50.31 3.81 8.19% |
For Janux Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Janux Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Janux Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Janux Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Janux Therapeutics over time as well as its relative position and ranking within its peers.
Janux |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Janux Therapeutics. If investors know Janux will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Janux Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Revenue Per Share 0.255 | Quarterly Revenue Growth (0.83) | Return On Assets (0.1) | Return On Equity (0.12) |
The market value of Janux Therapeutics is measured differently than its book value, which is the value of Janux that is recorded on the company's balance sheet. Investors also form their own opinion of Janux Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Janux Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Janux Therapeutics' market value can be influenced by many factors that don't directly affect Janux Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Janux Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Janux Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Janux Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Janux Therapeutics Return On Asset vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Janux Therapeutics's current stock value. Our valuation model uses many indicators to compare Janux Therapeutics value to that of its competitors to determine the firm's financial worth. Janux Therapeutics is rated fifth overall in shares outstanding category among its peers. It also is rated fifth overall in return on asset category among its peers . Return On Assets is likely to drop to -0.16 in 2024. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Janux Therapeutics' earnings, one of the primary drivers of an investment's value.Janux Return On Asset vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Janux Therapeutics |
| = | 52.48 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Janux Therapeutics |
| = | -0.0993 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Janux Return On Asset Comparison
Janux Therapeutics is currently under evaluation in return on asset category among its peers.
Janux Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Janux Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Janux Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Janux Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Janux Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 665 K | 698.2 K | |
| Net Interest Income | 12.5 M | 13.1 M | |
| Operating Income | -73 M | -69.3 M | |
| Net Loss | -62.6 M | -59.5 M | |
| Income Before Tax | -58.3 M | -55.4 M | |
| Total Other Income Expense Net | 14.7 M | 15.4 M | |
| Net Loss | -56.8 M | -53.9 M | |
| Net Loss | -58.3 M | -55.4 M | |
| Income Tax Expense | 1.8 M | 1.9 M | |
| Interest Income | 12.5 M | 13.1 M | |
| Non Operating Income Net Other | 4.6 M | 2.4 M | |
| Change To Netincome | 19.8 M | 20.8 M | |
| Net Loss | (1.32) | (1.39) | |
| Income Quality | 0.87 | 0.80 | |
| Net Income Per E B T | 0.99 | 1.01 |
Janux Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Janux Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Janux Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Janux Therapeutics' important profitability drivers and their relationship over time.
Use Janux Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Janux Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Janux Therapeutics will appreciate offsetting losses from the drop in the long position's value.Janux Therapeutics Pair Trading
Janux Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Janux Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Janux Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Janux Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Janux Therapeutics to buy it.
The correlation of Janux Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Janux Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Janux Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Janux Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Janux Therapeutics position
In addition to having Janux Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Market Funds Thematic Idea Now
Money Market Funds
Funds or Etfs investing in various types of short-term (less than one year) fixed income instruments of high-quality and liquidity. The Money Market Funds theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Market Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.